Afrezza Revolutionizes Diabetes Care with Inhalable Insulin

Afrezza is the first and sole noninjection insulin created for individuals with both type 1 and type 2 diabetes mellitus. Afrezza, created and produced by MannKind Corporation (MannKind) in the USA, is intended to enhance glycemic control in adult individuals with diabetes mellitus. Cipla stated it will provide this medication to everyone, enabling millions to manage their health more easily.

Cipla announced on Wednesday that it has obtained approval from the Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza - inhalation human insulin in India.

Afrezza is a fast-acting insulin administered via an inhaler, unlike existing insulins that are provided as injections. Administered at the start of a meal, Afrezza swiftly dissolves when inhaled orally into the lungs, providing insulin promptly to the bloodstream.

Cipla stated that Afrezza begins to take effect in as little as 12 minutes and aids in lowering the rapid spike in sugar levels associated with meals. The impact of Afrezza persists for roughly 2-3 hours and it closely mimics the body’s natural reaction to insulin.

Cipla has conducted a phase 3 clinical trial conducted in 216 patients in India showed a significant reduction in HbA1c levels with Afrezza when added to oral antidiabetes medications.